
Sensorion SA (ALSEN) | Financial Analysis & Statements
Sensorion SA | Small-cap | Healthcare
Sensorion SA | Small-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
89.3M
Total Liabilities
17.1M
Shareholders Equity
72.1M
Debt to Equity
0.24
Cash Flow Metrics
Revenue & Profitability Trend
Sensorion SA Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 0 | 0 | 4.0M | 3.3M | 1.9M |
Cost of Goods Sold | - | - | - | - | - |
Gross Profit | - | - | - | - | - |
Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 25.7M | 22.8M | 22.9M | 14.6M | 7.7M |
Selling, General & Administrative | 4.5M | 2.4M | 130.6K | 106.0K | 99.4K |
Other Operating Expenses | -3.7M | -4.4M | 1.8M | 2.1M | 1.5M |
Total Operating Expenses | 26.4M | 20.8M | 24.9M | 16.8M | 9.3M |
Operating Income | -28.4M | -22.3M | -23.1M | -15.0M | -8.9M |
Operating Margin % | 0.0% | 0.0% | -574.1% | -449.8% | -463.0% |
Non-Operating Items | |||||
Interest Income | 2.9M | 708.0K | 95.6K | 53.6K | 43.4K |
Interest Expense | 251.0K | 109.0K | 168.0K | 165.7K | 132.3K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -25.8M | -21.8M | -23.2M | -15.1M | -9.0M |
Income Tax | 126.0K | 297.0K | 0 | 0 | 0 |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -26.0M | -22.1M | -23.2M | -15.1M | -9.0M |
Net Margin % | 0.0% | 0.0% | -576.8% | -453.8% | -468.7% |
Key Metrics | |||||
EBITDA | -25.4M | -21.5M | -22.3M | -14.5M | -8.5M |
EPS (Basic) | -€0.09 | -€0.18 | -€0.29 | -€0.19 | -€0.15 |
EPS (Diluted) | -€0.09 | -€0.18 | -€0.29 | -€0.19 | -€0.15 |
Basic Shares Outstanding | 283969129 | 122501538 | 79837084 | 79691358 | 60760952 |
Diluted Shares Outstanding | 283969129 | 122501538 | 79837084 | 79691358 | 60760952 |
Income Statement Trend
Sensorion SA Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 66.8M | 37.0M | 26.2M | 50.0M | 62.2M |
Short-term Investments | 10.2M | - | - | - | - |
Accounts Receivable | - | - | - | - | - |
Inventory | - | - | - | - | - |
Other Current Assets | - | 8.7K | 14.1K | 545.5K | 34.7K |
Total Current Assets | 85.7M | 43.3M | 35.8M | 56.9M | 66.4M |
Non-Current Assets | |||||
Property, Plant & Equipment | 3.2M | 2.3M | 1.7M | 1.0M | 653.7K |
Goodwill | 746.0K | 506.0K | 483.1K | 569.7K | 589.6K |
Intangible Assets | 746.0K | 506.0K | 478.3K | 569.7K | 589.6K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 3.0K | -211.0K | - | -1 | 1 |
Total Non-Current Assets | 3.6M | 3.2M | 3.2M | 2.1M | 1.5M |
Total Assets | 89.3M | 46.5M | 38.9M | 59.1M | 67.9M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 6.9M | 3.7M | 7.3M | 5.0M | 2.2M |
Short-term Debt | 1.2M | 1.1M | 1.2M | 711.4K | 303.1K |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 91.0K | 237.0K | 477.5K | 400.0K | 170.0K |
Total Current Liabilities | 13.7M | 9.6M | 13.6M | 10.5M | 4.3M |
Non-Current Liabilities | |||||
Long-term Debt | 1.0M | 1.8M | 2.6M | 3.4M | 3.6M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 2.2M | 1.6M | 681.5K | 1.0M | 1.5M |
Total Non-Current Liabilities | 3.5M | 3.6M | 3.5M | 4.5M | 5.2M |
Total Liabilities | 17.1M | 13.2M | 17.1M | 15.0M | 9.5M |
Equity | |||||
Common Stock | 30.1M | 18.7M | 8.0M | 8.0M | 8.0M |
Retained Earnings | -61.9M | -58.6M | -23.2M | -15.1M | -9.0M |
Treasury Stock | 82.0K | 86.0K | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 72.1M | 33.3M | 21.9M | 44.1M | 58.4M |
Key Metrics | |||||
Total Debt | 2.2M | 2.9M | 3.9M | 4.1M | 3.9M |
Working Capital | 72.0M | 33.7M | 22.2M | 46.4M | 62.2M |
Balance Sheet Composition
Sensorion SA Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -26.0M | -22.1M | -23.2M | -15.1M | -9.0M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 1.0M | 298.0K | 1.1M | 561.1K | 359.0K |
Working Capital Changes | 184.0K | -831.0K | -2.5M | 482.9K | 2.2M |
Operating Cash Flow | -24.7M | -22.5M | -24.6M | -14.1M | -6.3M |
Investing Activities | |||||
Capital Expenditures | -705.0K | -657.0K | -1.4M | -470.0K | -75.8K |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | -6.1K | -29.6K | -33.3K | 0 |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -719.0K | -669.1K | -1.5M | -503.3K | -75.8K |
Financing Activities | |||||
Share Repurchases | - | - | - | - | -3.4K |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | -893.0K | -1.1M | - | - | -20.0M |
Financing Cash Flow | 67.0M | 33.1M | -488.0K | -557.6K | 37.3M |
Free Cash Flow | -22.5M | -21.6M | -22.9M | -11.4M | -5.5M |
Net Change in Cash | 41.5M | 10.0M | -26.5M | -15.2M | 31.0M |
Cash Flow Trend
Sensorion SA Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-3.63
Forward P/E
-2.52
Price to Book
1.36
Price to Sales
16.08
PEG Ratio
-2.52
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-371.94%
Return on Equity
-49.28%
Return on Assets
-26.15%
Financial Health
Current Ratio
6.28
Debt to Equity
2.93
Beta
1.13
Per Share Data
EPS (TTM)
-€0.09
Book Value per Share
€0.24
Revenue per Share
€0.02
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
alsen | 107.0M | -3.63 | 1.36 | -49.28% | 0.00% | 2.93 |
Medincell S.A | 557.6M | -18.19 | - | 61.33% | -66.50% | -1.44 |
Abivax SA | 547.1M | -3.08 | -82.88 | -196.12% | 0.00% | -16.16 |
Innate Pharma S.A | 158.3M | -2.82 | 16.36 | -162.91% | -245.87% | 350.86 |
Ose | 120.5M | 3.61 | 1.81 | 86.29% | 44.88% | 72.30 |
Transgene S.A | 110.8M | - | 6.96 | -220.48% | 0.00% | 68.38 |
Financial data is updated regularly. All figures are in the company's reporting currency.